Welcome to the 3rd TCR-based Therapies for Solid Tumors Summit

2022 marks a crucial stage in the history of TCR therapies, with the first commercial TCR therapy approval for Immunocore and IND clearances for Lion TCR and Lyell Immunopharma paving the way for future developments.

Uniting industry professionals in Boston to collaborate and further the progression and expansion of TCR therapies, the TCR-based Therapies for Solid Tumors Summit remains your one-stop shop to gain exclusive insights from companies leading the way in targeting, discovery and commercialization.

Join us in person to delve into all your TCR challenges and learn how to:

Icons 1

Enhance TCR discovery to ensure optimal targeting of tumor-specific antigens whilst preventing cross-reactivity and toxicity with Anocca, T-Cypher Bio and Gadeta

Increase TCR efficacy by exploring novel approaches and their benefits to expand TCR therapy repertoire beyond TCR-Ts with Alloy Therapeutics, Eureka Therapeutics and Ziopharm Oncology


Progress antigen discovery and selection to expand target range and redefine tumor-specific targeting with Affini-T, TScan, Immunoscape and 3T Biosciences


Pioneer strategies to overcome manufacturing and preclinical difficulties to accelerate preclinical and clinical development with TCR2 Therapeutics, Adaptimmune and Amgen

Promote cell fitness, persistence and infiltration through cell engineering to overcome the hostile and heterogeneous solid tumor microenvironment with Kite, University of Colorado Anschutz Medical Campus, Seattle Children’s and Adaptimmune